BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 24577458)

  • 1. Do cholinesterase inhibitors act primarily on attention deficit? A naturalistic study in Alzheimer's disease patients.
    Bracco L; Bessi V; Padiglioni S; Marini S; Pepeu G
    J Alzheimers Dis; 2014; 40(3):737-42. PubMed ID: 24577458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cholinesterase inhibitors on attention.
    Pepeu G; Giovannini MG; Bracco L
    Chem Biol Interact; 2013 Mar; 203(1):361-4. PubMed ID: 23047023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A qualitative analysis of the mini mental state examination on Alzheimer's disease patients treated with cholinesterase inhibitors.
    Lucchi E; Minicuci N; Magnifico F; Mondini S; Calza A; Avanzi S; Villani D; Bellelli G; Trabucchi M
    Arch Gerontol Geriatr Suppl; 2004; (9):253-63. PubMed ID: 15207422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early onset Alzheimer's disease is associated with a distinct neuropsychological profile.
    Smits LL; Pijnenburg YA; Koedam EL; van der Vlies AE; Reuling IE; Koene T; Teunissen CE; Scheltens P; van der Flier WM
    J Alzheimers Dis; 2012; 30(1):101-8. PubMed ID: 22366769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
    López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
    Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
    Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
    Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of lexical-semantic treatment on memory in early Alzheimer disease: an observer-blinded randomized controlled trial.
    Jelcic N; Cagnin A; Meneghello F; Turolla A; Ermani M; Dam M
    Neurorehabil Neural Repair; 2012 Oct; 26(8):949-56. PubMed ID: 22460609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
    Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
    Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
    Crowell TA; Paramadevan J; Abdullah L; Mullan M
    J Geriatr Psychiatry Neurol; 2006 Mar; 19(1):13-5. PubMed ID: 16449754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategic subcortical hyperintensities in cholinergic pathways and executive function decline in treated Alzheimer patients.
    Behl P; Bocti C; Swartz RH; Gao F; Sahlas DJ; Lanctot KL; Streiner DL; Black SE
    Arch Neurol; 2007 Feb; 64(2):266-72. PubMed ID: 17296844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.
    Goekoop R; Scheltens P; Barkhof F; Rombouts SA
    Brain; 2006 Jan; 129(Pt 1):141-57. PubMed ID: 16251213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease.
    Velayudhan L; Proitsi P; Westman E; Muehlboeck JS; Mecocci P; Vellas B; Tsolaki M; Kłoszewska I; Soininen H; Spenger C; Hodges A; Powell J; Lovestone S; Simmons A;
    J Alzheimers Dis; 2013; 33(3):755-66. PubMed ID: 23047370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
    Borkowska A; Ziolkowska-Kochan M; Rybakowski JK
    Hum Psychopharmacol; 2005 Aug; 20(6):409-14. PubMed ID: 15991260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion of amnestic Mild Cognitive Impairment to dementia of Alzheimer type is independent to memory deterioration.
    Rozzini L; Chilovi BV; Conti M; Bertoletti E; Delrio I; Trabucchi M; Padovani A
    Int J Geriatr Psychiatry; 2007 Dec; 22(12):1217-22. PubMed ID: 17562522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
    Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
    Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of AZD3480 on cognition in patients with mild-to-moderate Alzheimer's disease: a phase IIb dose-finding study.
    Frölich L; Ashwood T; Nilsson J; Eckerwall G;
    J Alzheimers Dis; 2011; 24(2):363-74. PubMed ID: 21258153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: implications for early diagnosis and treatment.
    Molinuevo JL; Berthier ML; Rami L
    Arch Gerontol Geriatr; 2011; 52(1):18-22. PubMed ID: 19948364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.